Royalty Pharma plc Investment Income, Net
Royalty Pharma plc (RPRX) reported Investment Income, Net of $72.29 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2024-02-15
- Royalty Pharma plc investment income, net for the quarter ending 2023-12-31 was $6.50M, a 85.18% decline year-over-year.
- Royalty Pharma plc investment income, net for the quarter ending 2023-09-30 was $23.44M, a 66.99% increase year-over-year.
- Royalty Pharma plc investment income, net for the quarter ending 2023-06-30 was $25.65M, a 134.94% increase year-over-year.
- Royalty Pharma plc investment income, net for the quarter ending 2023-03-31 was $16.70M, a 75.28% increase year-over-year.
- Royalty Pharma plc investment income, net for fiscal 2023 was $72.29M, a 7.72% decline from fiscal 2022.
- Royalty Pharma plc investment income, net for fiscal 2022 was $78.33M, a 46.32% increase from fiscal 2021.
- Royalty Pharma plc investment income, net for fiscal 2021 was $53.53M, a 88.64% increase from fiscal 2020.
- Royalty Pharma plc investment income, net for fiscal 2020 was $28.38M, a 27.09% increase from fiscal 2019.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2023-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $29.94M derived: sum of 2 quarters · filed 2024-02-15 | $55.59M derived: sum of 3 quarters · filed 2024-02-15 | $72.29M 10-K · filed 2024-02-15 |
| 2023-09-30 | $23.44M 10-Q · filed 2023-11-08 | $49.09M derived: sum of 2 quarters · filed 2023-11-08 | $65.79M 10-Q · filed 2023-11-08 | $109.64M derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-06-30 | $25.65M 10-Q · filed 2023-08-08 | $42.35M 10-Q · filed 2023-08-08 | $86.21M derived: sum of 3 quarters · filed 2024-02-15 | $100.24M derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-03-31 | $16.70M 10-Q · filed 2023-05-09 | $60.55M derived: sum of 2 quarters · filed 2024-02-15 | $74.59M derived: sum of 3 quarters · filed 2024-02-15 | $85.51M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-12-31 | $43.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $57.89M derived: sum of 2 quarters · filed 2024-02-15 | $68.81M derived: sum of 3 quarters · filed 2024-02-15 | $78.33M 10-K · filed 2024-02-15 |
| 2022-09-30 | $14.03M 10-Q · filed 2023-11-08 | $24.95M derived: sum of 2 quarters · filed 2023-11-08 | $34.48M 10-Q · filed 2023-11-08 | $45.12M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $10.92M 10-Q · filed 2023-08-08 | $20.45M 10-Q · filed 2023-08-08 | $31.09M derived: sum of 3 quarters · filed 2024-02-15 | $43.35M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $9.53M 10-Q · filed 2023-05-09 | $20.17M derived: sum of 2 quarters · filed 2024-02-15 | $32.43M derived: sum of 3 quarters · filed 2024-02-15 | $46.47M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $22.90M derived: sum of 2 quarters · filed 2024-02-15 | $36.94M derived: sum of 3 quarters · filed 2024-02-15 | $53.53M 10-K · filed 2024-02-15 |
| 2021-09-30 | $12.26M 10-Q · filed 2022-11-08 | $26.30M derived: sum of 2 quarters · filed 2022-11-08 | $42.90M 10-Q · filed 2022-11-08 | $64.11M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $14.04M 10-Q · filed 2022-08-04 | $30.64M 10-Q · filed 2022-08-04 | $51.84M derived: sum of 3 quarters · filed 2023-02-15 | $53.43M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $16.60M 10-Q · filed 2022-05-05 | $37.81M derived: sum of 2 quarters · filed 2023-02-15 | $39.40M derived: sum of 3 quarters · filed 2023-02-15 | $42.12M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $21.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $22.80M derived: sum of 2 quarters · filed 2023-02-15 | $25.52M derived: sum of 3 quarters · filed 2023-02-15 | $28.38M 10-K · filed 2023-02-15 |
| 2020-09-30 | $1.59M 10-Q · filed 2021-11-10 | $4.31M derived: sum of 2 quarters · filed 2021-11-10 | $7.17M 10-Q · filed 2021-11-10 | $10.42M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $2.72M 10-Q · filed 2021-08-11 | $5.58M 10-Q · filed 2021-08-11 | $8.83M derived: sum of 3 quarters · filed 2022-02-15 | $13.41M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $2.86M 10-Q · filed 2021-05-11 | $6.11M derived: sum of 2 quarters · filed 2022-02-15 | $10.69M derived: sum of 3 quarters · filed 2022-02-15 | $15.16M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $7.83M derived: sum of 2 quarters · filed 2022-02-15 | $12.30M derived: sum of 3 quarters · filed 2022-02-15 | $22.33M 10-K · filed 2022-02-15 |
| 2019-09-30 | $4.58M 10-Q · filed 2020-11-12 | $9.05M derived: sum of 2 quarters · filed 2020-11-12 | $19.08M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $4.47M 10-Q · filed 2020-08-12 | $14.50M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $24.44M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |